Abstract: Improved emulsions of highly fluorinated organic compounds. The emulsions comprise a highly fluorinated organic compound, an oil, that is not substantially surface active and not significantly water soluble, and a surfactant. They are characterized by a well-defined relationship in the relative amounts of the three components.

Abstract: This disclosure relates to a method of treating a neurological dysfunction in a mammal using a combination of at least one neurotransmitter enhancer and at least one serotonin receptor antagonist.

Abstract: Ruminants such as cattle are protected against selenium-deficient diseases by applying a sulfur-selenium composition to the rangelands or pasturelands where the cattle graze. The composition preferably contains the selenium in a solid solution in the sulfur.

Abstract: Pharmaceutical compositions for enhancing the process of learning and memory are disclosed, that contain as active principle a 3-amino-.epsilon.-caprolactam of formula (1) ##STR1## Wherein R is selected from the group consisting of hydrogen, formyl and acetyl.Orally or parenterally administrable pharmaceutical compositions in unit dosage form comprise from about 100 to about 500 mg of a compound of formula (1).

Abstract: A method for enhancing the systemic delivery of dextromethorphan for the treatment of a neurological disorder resulting in injury to nervous tissue, which comprises administering to a patient suffering from the disorder an amount of a cytochrome P450IID6 enzyme inhibitor, sufficient to block dextromethorphan metabolism, and an amount of dextromethorphan sufficient to treat the neurological disorder. Quinidine is particularly suitable for use in the method of the invention.

Abstract: There is disclosed a stable pharmaceutical composition containing nicardipine hydrochloride, a non-chloride isotonicity agent, a buffering agent and a pharmaceutically acceptable aqueous vehicle for parenteral administration.

Abstract: This invention relates to pharmaceutical compositions for use in the treatment of pain and inflammation and the relief of cough and cold symptoms in a mammalian organism, said composition comprising:(i) an analgesically and anti-inflammatory effective amount of (S)-ibuprofen, or a salt thereof, substantially free of (R)-ibuprofen; and(ii) an antitussively effective amount of at least one antitussive agent selected from codeine, hydrocodone, caramiphen, carbetapentane, or dextromethorphan, or a therapeutically active stereoisomer thereof substantially free of its other stereoisomers and optionallyiii) a therapeutically effective amount of at least one expectorant selected from guaicolsulfonate, guaifenesin, guaiacol, or terpin;or a pharamceutically acceptable salt thereof.

Abstract: There is provided a novel therapeutic product for use in the symptomatic treatment of cystic fibrosis and for use in the manufacture of a medicament for the treatment of cystic fibrosis, as well as a method for treatment of cystic fibrosis with the therapeutic product and a method of treatment of cystic fibrosis with the therapeutic product in combination with one or more other agents indicated for the treatment of cystic fibrosis.

Abstract: Pharmaceutical compositions for enhancing absorption of a topically administered formulation through dermal or mucosal membrane, for local or systemic application, comprising one or more agents of formula I: ##STR1## where: R is a saturated or unsaturated, straight or branched, cyclic or acyclic hydrocarbon group with from 1 to 19 carbon atoms or an alkoxyalkyl group; n is 2-20; X is selected from H, OR.sub.2 or NR.sub.2 R.sub.3 ; wherein R.sub.1, R.sub.2 and R.sub.3 are independently selected from H, alkyl, haloalkyl, acyl, carbalkoxy, carbalkoxyalkyl, hydroyalkyl, acyloxyalkyl, alkoxyalkyl, aminoalkyl- and acylaminoalkyl; i) with the proviso that when n is 2, X is OR.sub.2 and R.sub.2 is H, then R.sub.1 is not hydroxyalkyl, specifically, 2-hydroxyethyl; and ii) with the proviso that when n is 2 and X is NR.sub.2 R.sub.3, then R.sub.1 and R.sub.2 may combine to form a heterocyclic ring and R.sub.3 is not acyl; and iii) with the proviso that when X is NR.sub.2 R.sub.3, then R.sub.2 and R.sub.

Abstract: A method for treating inflammation in a patient which comprises administering to the patient a therapeutically effective amount of a compound of the formula: ##STR1## wherein A and R.sub.1 -R.sub.6 are defined herein.

Abstract: Flupirtine is used for the treatment of disorders involving skeletal muscle tension.

Abstract: Magnetic liquid compositions are prepared from physiologically tolerated dispersions of stabilized superparamegnetic particles in water or aqueous salt solution and reactive stabilizer substances chemically bonded over phosphate, phosphonate or carboxylate groups to the surface of the superparamagnetic particles. The reactive stabilizer substances stabilize and chemically bond diagnostic and pharmacologically active substances.

Abstract: A method of inhibiting neuronal injury or death in a human patient comprising administering an inhibitor of enzymatic conversion of glutamine to glutamate in an amount sufficient to inhibit the conversion of glutamine to glutamate.

Abstract: A method of treating a disease in a mammal, including a human, responsive to blockade of potassium channels, which comprises administering to a mammal in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sup.11, R.sup.12, R.sup.13, R.sup.14 and R.sup.15 independently of each other are hydrogen, CF.sub.3, NO.sub.2, NH.sub.2, OH, C.sub.1-6 -alkyl, C.sub.1-6 -alkoxy or phenyl; andR.sup.4, R.sup.5, R.sup.6 and R.sup.7 independently of each other are hydrogen, halogen, CF.sub.3, C.sub.1-6 -alkyl, NO.sub.2, NH.sub.2, OH or C.sub.1-6 -alkoxy,and a method as above wherein 1-(4-methoxyphenyl)-indole is employed,and a method as above wherein depression, memory disorders, Alzheimers disease and diabetes 2 is treated,and further a method as above wherein the active ingredient is administered in the form of a pharmaceutical composition thereof, in which it is present together with a pharmaceutically-acceptable carrier or diluent.

Abstract: Stearidonic acid is administered to mammals for inhibiting biosynthesis of leukotrienes.

Abstract: Polysulfonated compounds such as suramin are used to treat immunoregulatory isorders. Particular use in the treatment of rheumatologic diseases such as rheumatoid arthritis is shown.

Abstract: This invention relates to the use of 3-aryl-5-alkylthio-4H-1,2,4-triazoles and the corresponding alkylsulfinyl- and alkylsulfonyl-4H-1,2,4-triazoles in the treatment of patients suffering from chronic hyperreflexia due to spinal trauma.

Abstract: The invention relates to new thieno-triazolo-1,4-diazepino-2-carboxylic acid amides of formula I ##STR1## wherein R.sub.1 represents hydrogen, a C.sub.1 -C.sub.4 straight-chained or branched alkyl which can optionally be substituted by halogen, preferably Cl or Br, or by hydroxy, cyclopropyl, C.sub.1 -C.sub.3 alkoxy, preferably methoxy, or halogen, preferably chlorine or bromine;R.sub.2 and R.sub.3, each independently, represent hydrogen, a C.sub.1 -C.sub.4 straight-chained or branched alkyl, C.sub.1 -C.sub.4 hydroxyalkyl or the two groups R.sub.2 and R.sub.3 together with the nitrogen atom represent a 5-, 6- or 7-membered ring which optionally contains a nitrogen, oxygen or sulfur atom as a further heteroatom, the second nitrogen atom optionally being substituted by a C.sub.1 -C.sub.4 alkyl, preferably a methyl group;R.sub.

Abstract: A pharmaceutical composition for relieving symptoms of dysmenorrhea and/or premenstrual syndrome comprising a combination of ibuprofen and hydrochlorothiazide.

Abstract: A method of treating cerebral apoplexy in a patient in need thereof which comprises administering to said patient an amount effective therefor of a serotonin agonist which has a binding strength of less than 10,000 nmol/l on binding to 5HT.sub.1A receptors.